Phase 1 N=75 Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
Lymphoma · Leukemia
Primary: Dose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab — NA mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=32 Pazopanib and ARQ 197 for Advanced Solid Tumors
Solid Tumor
Primary: Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant — 1; 0; 0; 0 Adverse events
Phase 1 N=20 Fluoride Retention in the Mouth of Older Adults
Hyposalivation
Primary: Fluoride Concentration in Dental Biofilm Fluid at Baseline — 0.24; 0.22 parts per million (ppm) of fluoride — p=0.8412
Phase 1 N=16 A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution
Normal Healthy Volunteers
Primary: Mean Maximum Plasma Concentration (Cmax) — 0.6984; 0.7275; 0.6977 ng/mL
Phase 1 N=12 Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida
Candida Infection · Premature Infant
Primary: Stool Fungal Burden — 500; 55000; 1671; 622.5 cfu per gram — p=0.9
Phase 1 N=32 Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions
Bioequivalence
Primary: Concentration Maximum (Cmax) — 1.326; 1.293 ng/ml
Phase 1 N=32 Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions
Bioequivalence
Primary: Concentration Maximum (Cmax) — 0.9092; 0.8711 ng/ml
Phase 1 N=32 A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
Healthy Subjects · Drug-drug Interaction · Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) Following Single Dose of Quizartinib With or Without Efavirenz — 130.0; 238.0; 11.0; 34.4 ng/mL
Phase 1 N=26 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Phase 1 N=49 Safety Study of Tezepelumab (AMG 157) in Healthy Adults
Healthy Volunteers
Primary: Number of Participants With Treatment-emergent Adverse Events — 4; 4; 2; 6 Participants
Phase 1 N=22 Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline
Healthy Subjects
Primary: AUC0-t — 4.49; 98.74 h*ng/ml
Phase 1 N=20 Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults
HIV Infections
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine — 37970; 42230 Hour*nanograms per milliliter (h*ng/mL)
Phase 1 N=97 Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
Healthy · Chronic Rhinosinusitis With Nasal Polyps · Atopic Dermatitis
Primary: Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part 1 — 6; 4; 5; 3 Participants
Phase 1 N=24 Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 1; 0; 1; 3 Participants
Phase 1 N=24 Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Age-Related Maculopathy · Age-Related Maculopathies · Eye Diseases
Primary: Number of Participants With Toxicity or Intolerable Dose Criteria — 0; 0; 0; 0 Participants